Laurus Labs’ years-long capex gamble pays off as CDMO orders drive earnings, stock surge

Shares of Laurus Labs have nearly doubled over the past year due to a surge in Contract Development and Manufacturing Organization (CDMO) orders. This significant increase in orders, particularly from late-stage and commercial products, has transformed the company's earnings. As a result, Laurus Labs' years-long investment in capital expenditure (capex) has paid off, driving a stock surge. This turnaround is likely to have a positive impact on the Indian pharmaceutical sector, particularly the Nifty Pharma index.

Why it matters

The surge in CDMO orders has driven the earnings and stock price of Laurus Labs, making it a positive news story for the company and the pharmaceutical sector. The company's years-long capex gamble has paid off, and the stock has nearly doubled over the past

Market impact

Transmission channels

Likely winners & losers

Explore the intelligence

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to Moneycontrol. For information only — not financial advice.